This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Apr 2;387(10026):1372-1373.

doi: 10.1016/S0140-6736(16)30077-0.

PATHWAY-2: spironolactone for resistant hypertension

Aaron Dale¹, Philip Hartley¹, Ben Goldacre²; COMPare project team

Affiliations

Affiliations

¹ Centre for Evidence Based Medicine, Department of Primary Care Health Sciences, Oxford OX2 6NW, UK.
² Centre for Evidence Based Medicine, Department of Primary Care Health Sciences, Oxford OX2 6NW, UK. Electronic address: compare-team@ebmdatalab.net.

PMID: 27115813
DOI: 10.1016/S0140-6736(16)30077-0

Comment

PATHWAY-2: spironolactone for resistant hypertension

Aaron Dale et al. Lancet. 2016.

. 2016 Apr 2;387(10026):1372-1373.

doi: 10.1016/S0140-6736(16)30077-0.

Authors

Aaron Dale¹, Philip Hartley¹, Ben Goldacre²; COMPare project team

Affiliations

¹ Centre for Evidence Based Medicine, Department of Primary Care Health Sciences, Oxford OX2 6NW, UK.
² Centre for Evidence Based Medicine, Department of Primary Care Health Sciences, Oxford OX2 6NW, UK. Electronic address: compare-team@ebmdatalab.net.

PMID: 27115813
DOI: 10.1016/S0140-6736(16)30077-0

No abstract available

PubMed Disclaimer

Comment in

PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
Williams B, MacDonald TM, Morant SV, Brown MJ. Williams B, et al. Lancet. 2016 Apr 2;387(10026):1373-1374. doi: 10.1016/S0140-6736(16)00698-X. Lancet. 2016. PMID: 27115814 No abstract available.

Comment on

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Williams B, et al. Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20. Lancet. 2015. PMID: 26414968 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information